StockNews.com Begins Coverage on Nabriva Therapeutics (NASDAQ:NBRV)

Research analysts at StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research report issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. The firm has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.